During these neurological disorders, there is an overexpression of KV1.3 channels concluding that KV1.3 specific blockers could mitigate neuroinflammation, and become specific therapeutic candidates during AD or PD (reviewed in Revuelta et al., 2022). The gene discussed is KCNA3; the disease is nervous system disorder.